TSCAN THERAPEUTICS, INC. Interest Expense
TSCAN THERAPEUTICS, INC. (TCRX) reported Interest Expense of $699.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Expense Statement › Interest Expense
us-gaap:InterestExpense · last filed 2026-08-12
- TSCAN THERAPEUTICS, INC. interest expense for the quarter ending 2026-06-30 was $699.00K, a 1.45% increase year-over-year.
- TSCAN THERAPEUTICS, INC. interest expense for the quarter ending 2026-03-31 was $689.00K, a 1.47% increase year-over-year.
- TSCAN THERAPEUTICS, INC. interest expense for the quarter ending 2025-12-31 was $702.00K, a 10.46% decline year-over-year.
- TSCAN THERAPEUTICS, INC. interest expense for the quarter ending 2025-09-30 was $699.00K, a 27.04% decline year-over-year.
- TSCAN THERAPEUTICS, INC. interest expense for fiscal 2025 was $2.77M, a 24.20% decline from fiscal 2024.
- TSCAN THERAPEUTICS, INC. interest expense for fiscal 2024 was $3.65M, a 2.82% decline from fiscal 2023.
- TSCAN THERAPEUTICS, INC. interest expense for fiscal 2023 was $3.76M, a 219.64% increase from fiscal 2022.
- TSCAN THERAPEUTICS, INC. interest expense for fiscal 2022 was $1.18M.
| Period end | Interest Expense 3 month | Interest Expense 6 month | Interest Expense 9 month | Interest Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $699.00K 10-Q · filed 2026-08-12 | $1.39M 10-Q · filed 2026-08-12 | $2.09M derived: sum of 3 quarters · filed 2026-08-12 | $2.79M derived: sum of 4 quarters · filed 2026-08-12 |
| 2026-03-31 | $689.00K 10-Q · filed 2026-05-06 | $1.39M derived: sum of 2 quarters · filed 2026-05-06 | $2.09M derived: sum of 3 quarters · filed 2026-05-06 | $2.78M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-12-31 | $702.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-04 | $1.40M derived: sum of 2 quarters · filed 2026-03-04 | $2.09M derived: sum of 3 quarters · filed 2026-08-12 | $2.77M 10-K · filed 2026-03-04 |
| 2025-09-30 | $699.00K 10-Q · filed 2025-11-12 | $1.39M derived: sum of 2 quarters · filed 2026-08-12 | $2.07M 10-Q · filed 2025-11-12 | $2.85M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-06-30 | $689.00K 10-Q · filed 2026-08-12 | $1.37M 10-Q · filed 2026-08-12 | $2.15M derived: sum of 3 quarters · filed 2026-08-12 | $3.11M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-03-31 | $679.00K 10-Q · filed 2026-05-06 | $1.46M derived: sum of 2 quarters · filed 2026-05-06 | $2.42M derived: sum of 3 quarters · filed 2026-05-06 | $3.37M derived: sum of 4 quarters · filed 2026-05-06 |
| 2024-12-31 | $784.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-04 | $1.74M derived: sum of 2 quarters · filed 2026-03-04 | $2.69M derived: sum of 3 quarters · filed 2026-03-04 | $3.65M 10-K · filed 2026-03-04 |
| 2024-09-30 | $958.00K 10-Q · filed 2025-11-12 | $1.91M derived: sum of 2 quarters · filed 2025-11-12 | $2.87M 10-Q · filed 2025-11-12 | $3.72M derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | $952.00K 10-Q · filed 2025-08-12 | $1.91M 10-Q · filed 2025-08-12 | $2.76M derived: sum of 3 quarters · filed 2025-08-12 | $3.75M derived: sum of 4 quarters · filed 2025-08-12 |
| 2024-03-31 | $959.00K 10-Q · filed 2025-05-06 | $1.81M derived: sum of 2 quarters · filed 2025-05-06 | $2.79M derived: sum of 3 quarters · filed 2025-05-06 | $3.76M derived: sum of 4 quarters · filed 2025-05-06 |
| 2023-12-31 | $852.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-05 | $1.83M derived: sum of 2 quarters · filed 2025-03-05 | $2.80M derived: sum of 3 quarters · filed 2025-03-05 | $3.76M 10-K · filed 2025-03-05 |
| 2023-09-30 | $982.00K 10-Q · filed 2024-11-12 | $1.95M derived: sum of 2 quarters · filed 2024-11-12 | $2.91M 10-Q · filed 2024-11-12 | $3.88M derived: sum of 4 quarters · filed 2024-11-12 |
| 2023-06-30 | $969.00K 10-Q · filed 2024-08-12 | $1.93M 10-Q · filed 2024-08-12 | $2.90M derived: sum of 3 quarters · filed 2024-08-12 | $3.10M derived: sum of 4 quarters · filed 2024-08-12 |
| 2023-03-31 | $956.00K 10-Q · filed 2024-05-13 | $1.93M derived: sum of 2 quarters · filed 2024-05-13 | $2.13M derived: sum of 3 quarters · filed 2024-05-13 | |
| 2022-12-31 | $975.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-06 | $1.18M derived: sum of 2 quarters · filed 2024-03-06 | $1.18M 10-K · filed 2024-03-06 | |
| 2022-09-30 | $201.00K 10-Q · filed 2023-11-09 | $201.00K 10-Q · filed 2023-11-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CERO THERAPEUTICS HOLDINGS, INC. (CERO) | United States | $0.007B | |
| CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (CELZ) | United States | $0.006B | |
| AIM ImmunoTech Inc. (AIM) | United States | $0.006B | |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |
| IN8BIO, INC. (INAB) | United States | $0.012B | -0.76 |
| PharmaCyte Biotech, Inc. (PMCB) | United States | $0.005B | |
| BRAINSTORM CELL THERAPEUTICS INC. (BCLI) | United States | $0.013B | -1.05 |
| INTENSITY THERAPEUTICS, INC. (INTS) | United States | $0.013B | -1.08 |
| WINDTREE THERAPEUTICS INC /DE/ (WINT) | United States | $0.003B | -0.32 |
| VivoSim Labs, INC. (VIVS) | United States | $0.003B |